Dr Reddy’s Q2 Preview: PAT may grow up to 11–18% YoY; revenue seen steady despite pricing pressure in US by ET Markets | October 23, 2025 4:04 pm | Indian Stocks, Market, News Dr Reddy’s Laboratories is expected to post steady September-quarter earnings with 10–14% revenue growth led by India and Europe, though US pricing pressure and weaker product mix may compress margins. Brokerages project up to 18% YoY profit growth.
